Compare DuPont de Nemours Inc (DD) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DuPont de Nemours Inc vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? DuPont de Nemours Inc trades at $130.23 (market cap $17.89B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.96 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is the larger of the two by market cap, and DuPont de Nemours Inc pays the higher dividend (1.81%). Which is the better fit depends on your goals — on Pluang, investors hold DuPont de Nemours Inc for 89 Days and Royalty Pharma plc Class A Ordinary Shares for 1 Days on average.
| DD | RPRX | |
|---|---|---|
Market Cap | $17.89B | $25.27B |
Volume | 816,409 | 3,671,183 |
Sector | Basic Materials | Health |
52-Week High | $154.59 | $63.96 |
52-Week Low | $92.49 | $35.44 |
Typical Hold Time | 89 Days | 1 Days |
Enterprise Value | $19.28B | $32.50B |
Dividend Yield | 1.81% | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DuPont (DD) trades at $130.53, down 0.42% on the day, with a neutral technical signal and bearish moving average trend. The company reported a net loss of $779 million in 2025 despite beating EPS estimates in recent quarters, with revenue declining to $6.85 billion. Analyst consensus is bullish with 59% buy ratings, though the consensus price target of $95 is below the current price. Recent news highlights innovation in Tyvek materials and digital tools, alongside legal settlements over PFAS contamination.
The outlook is mixed: strong analyst support and product innovation offer upside, but recent profitability challenges, high P/E ratio, and legal liabilities pose risks. Earnings growth and margin recovery are critical for sustaining investor confidence amid volatile cash flows and competitive pressures.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DuPont de Nemours Inc
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Read more on DD →About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →
